A psychedelic trial's most important result may be the outcome it missed

Source: Journal of Affective Disorders, published/indexed October 30, 2026; randomized double-blind pilot in treatment-resistant depression, original record, DOI 10.1016/j.jad.2026.122676. Evidence: small randomized pilot. Clinical state: investigational, supervised clinical research only.

Anhedonia—the loss of the ability to enjoy ordinary life—is often one of the hardest aspects of major depression to treat. Investigators randomly assigned 20 patients to psilocybin 25 mg or 1 mg, with psychological support. The prespecified primary endpoint was improvement on a measure of anhedonia after one week. The between-group difference was 11.2 points, but its 95% confidence interval ran from −1.0 to 23.3, and p=0.073. In other words, the study did not establish the primary superiority claim.

Secondary results were more encouraging. At week eight, the anhedonia difference on the same scale was 14.7 points (95% CI 2.5–26.8); overall depression severity also favored the higher dose at weeks one and eight. Those findings merit replication, but the small pilot, multiple endpoints, psychologically active treatment and potential functional unblinding limit what can be concluded about durability and generalizability.

What this changes: The result belongs in a serious mental-health edition because it identifies both a plausible direction for research and a failed primary test. Neither a promising secondary measure nor an early clinical signal makes unsupervised psychedelic use appropriate.